Parimal Pande
Ph.D. Student (2014-2021)
Current Position: Senior Scientist at Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
Education
2004-2008
B. Pharm in Pharmacy
University of Pune, India
2008-2010
MS In Biotechnology
University of Houston-Clear Lake
2014-2021
Ph.D. degree in Pharmacology
University of Connecticut
Professional Appointments
2009-2010
Laboratory Technician
SeqWright Inc., Houston, TX
2010-2012
Research Associate I
SeqWright Inc., Houston, TX
2012-2018
Scientist II
Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
2018-
Scientist III
Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
Professional Societies
2016-
Member, Society of Toxicology
Honors and Awards
2002
Prachchya Vidyapith Scholarship (Sanskrit)
2004
Open Merit Scholarship, Govt. of Maharashtra
2005
Sir Ratan Tata Scholarship, Sir Ratan Tata Trust
2008
Maharashtra State Ele. Board Scholarship for four years
2009
Endowment Scholarship, University of Houston Clear-Lake
2013
Boehringer Ingelheim REACH Award Excellence in Action in vitro MOA Study
2013
Boehringer Ingelheim REACH Award Excellence in Action RNA-Seq MOA Study
2018
Outstanding Reviewer Award Experimental Biology and Medicine
Poster Presentations
03/2014
SOT Meeting, Phoenix, AZ
Pande P, Yuan J, Hill J, Ku W. Next Generation sequencing reveals baseline gender and species differences in renal transcript expression in the CD-1 mouse and wistar Han rat.
03/2014
SOT Meeting, Phoenix, AZ
Yuan J, Pande P, Hill J, Wang Y, Mikl J, Hall D, Ku W. RNA-Seq reveals molecular changes in renal injury associated with exposure to empagliflozin in the male CD-1 mouse.
08/2016
Development Leadership Forum at Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
Applications of next generation sequencing in toxicology
03/2017
SOT Meeting, Baltimore, MD
ANG2/DLL4 blockade mediated angiogenesis signaling and induced cardiopathological changes in rat and cynomolgus monkey
03/2018
SOT Meeting, San Antonio, TX
Quantitative, accessible and translational biomarkers of gastrointestinal toxicity
03/2018
SOT Meeting, San Antonio, TX
miRNAs as pre-clinical predictive biomarker for characterization of cardiotoxicity mechanisms
04/2020
Experimental Biology Meeting
Pande P, Zhong XB, and Ku W. Histone 3 lysine 9 methylating enzyme G9a is involved in transcriptional regulation of expression of nuclear receptors and cytochrome P450 genes in HepaRG cells.
Publications
Knight B, Yuan J, Koegler S, Pande P, Hall J, Hill JD, Hart SE, Phillips JA, Ku WW. Pathogenesis of renal injury and gene expression changes in the male CD-1 mouse associated with exposure to empagliflozin. Toxicologic Pathology, 2018, 46(6):671-682. PMID:29945496. DOI:10.1177/0192623318784514.
Pande P, Giambalvo M, and Huang Z. Complementing preclinical safety assessments through genomic analyses. Current Opinion in Toxicology, 2019, DOI:10.1016/j.cotox.2019.01.002.
Pande P, Zhong XB, and Ku W. Histone methyltransferase G9a regulates expression of nuclear receptors and cytochrome P450 enzymes in HepaRG cells at basal level and in fatty acid induced steatosis. Drug Metabolism and Disposition, 48(12):1321-1329. PMID:33077425. DOI:10.1124/dmd.120.000195.
Ph.D. Thesis
Pande P, Role of histone methyltransferase enzyme G9a in transcriptional regulation of nuclear receptors and drug metabolizing P450 genes at basal level and in free fatty acid induced steatosis. Doctoral Dissertations, 2021.
